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The Ethics of Publishing Medical Imaging Research
Stephan Achenbach, MD,* Y. Chandrashekhar, MD,y Jagat Narula, MD, PHDz
Gießen, Germany; Minneapolis, Minnesota; and New York, New Yorklthough the editorial process is generally a
placid activity, whereby the collective wis-
dom of the reviewers and editors provides a
clear path, we are from time to time faced
with issues that generate a lot of animated debate.
This issue of iJACC contains a report that triggered
an important discussion among the Editorial Board.
Yin et al. (1) compared 2 different image acquisition
and reconstruction protocols for coronary computed
tomography (CT) angiography for their diagnostic
accuracy in 60 patients who underwent invasive
catheter-based coronary angiography for clinical
reasons. The investigators provide valuable insight
into radiation dose reduction that is possible using a
new iterative reconstruction algorithm in combina-
tion with modiﬁed image acquisition protocols.
Clearly, this was an important clinical question,
and the study was nicely done. However, all patients
underwent 2 separate coronary CT angiographic
acquisitions for research purposes, which of course
immediately caught our attention and generated
questions about the ethical implications of subject-
ing patients to 2 separate CT acquisitions, with the
associated contrast injections and radiation exposure,
purely for research purposes. Although the average
overall effective dose per patient was about 2.5
mSv (substantially lower than the dose of a single
coronary CT angiographic exam in numerous previ-
ous research protocols), we remain intrigued. What
would we have done if the radiation dose were
higher?Would the information in such a study justify
the higher risk to its participants? What range of
radiation would be unacceptable given that we are
unaware of a threshold dose below which radiation is
not harmful? Should such research have even been
allowed by the ethics committee in the ﬁrst place?From the *Medizinische Klinik I, Universitätsklinikum Gießen und
Marburg, Gießen, Germany; yUniversity of Minnesota, Minneapolis,
Minnesota, and VA Medical Center, Minneapolis, Minnesota; and the
zIcahn School of Medicine at Mount Sinai, New York, New York.Should research be published just because the study
has already been done?
Furthermore, although the investigators clearly
indicated that institutional review board (IRB)
approval had been obtained, how much more should
the editors of a journal police for research ethics,
when they perceive something as questionable?
Although no concern remained regarding this
particular report, this is not always the case. For
example, in a previously submitted (and ultimately
published) report, the researchers described cor-
onary CT angiographic investigations performed
before invasive workup of 87 patients admitted with
ST-segment elevation myocardial infarctions (2).
Although IRB approval had been obtained, the
report was accepted only after the Editorial Board
was convinced that patient treatment was not
delayed by the research CT. As should have been
the case, a discussion ensued after publication, with
a letter to the editor questioning the research and
publication ethics (3,4).
Because science is based on trust, journals usually
take submitted manuscripts at face value, respecting
the sanctity of IRB approval and the investigators’
assurance that the study was conducted ethically.
Clearly egregious cases are easily identiﬁed and de-
nied entry to the publication domain. What about
cases that are not so clear? Should editors question
research ethics beyond the mere requirement that
investigators obtain and indicate IRB approval, and
if so, how much further delving is reasonable? A
quick reﬂex answer would be in the afﬁrmative;
editors must police ethics. Such questions often do
not have straightforward answers. While we at
iJACC tend to fall on the more rigorous side of this
question (sometimes going beyond the investigators’
declarations to ascertain that proper IRB approval
was obtained and that all possible ethical rigor was
maintained in the conduct of a study), we continu-
ally remain cognizant of the intricacies (and sensi-
tivities) associated with such a question.
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1352Questioning research ethics, although a sensitive
issue, could be regarded as an editors’ right or as an
obligation, and we endorse this position strongly.
Clearly, the editors of a journal have the right to
pose speciﬁc questions to manuscript authors and
to require further explanation of critical aspects,
including ethics. Their scientiﬁc expertise will
typically go way beyond that of the members of an
IRB, and they may be able to recognize problems
where nonexperts would not. IRBs are chartered
differently in each country, often without accredi-
tation (5). Even regulatory agencies, let alone edi-
tors, often have no way of ascertaining the efﬁcacy
of an IRB (6) or that IRB approval means that the
approved research followed the best ethical stan-
dards. Others have been even more dismissive about
their performance (7). IRB expertise is highly vari-
able, and this, coupled with high workloads, means
that IRB approval is no guarantee that research has
the best possible risk-beneﬁt balance. A 2005 report
showed that IRBs at major research universities in
the United States had an average of 16 members,
and together they reviewed hundreds of proposals;
higher volume centers reviewed more than 1,000
proposals each year (8). These numbers have further
increased. Clearly, journals and editors have a crucial
role in making sure that research follows the best
ethical practices throughout the study, in addition to
whatever the IRB approved at the start of the study,
but remembering that the process is often difﬁcult
to accomplish fairly. It could also be an obligation if
a possible violation of basic ethical principles is
suspected. The Declaration of Helsinki in its latest
version, dating from 2008, clearly states, “Authors,
editors and publishers all have ethical obligations
with regard to the publication of the results of
research. Authors have a duty to make publicly
available the results of their research on human
subjects and are accountable for the completeness
and accuracy of their reports. Reports of research
not in accordance with the principles of this Decla-
ration should not be accepted for publication” (9).
Compliance with the rules of ethics in research
and its publication remains the responsibility of
study investigators, and the fact that a manuscript
passes through peer review and the editorial process
does not relieve the investigators of this respon-
sibility. Journals should not publish research that
does not comply, but they do not routinely require
copies of IRB approval, IRB membership rosters
(as contract research organizations seek during
industry-sponsored clinical trials), or the applications
that were submitted to obtain approval. Although
that may be considered desirable by some, it clearlywould be impossible given the multitude of countries
(with their local languages) represented by sub-
missions to international journals. It is also impor-
tant to note that the efﬁcacy of IRBs has not been
formally tested, and there is some argument regar-
ding whether, in their present form, they effectively
protect subjects (6). Not surprisingly, there have
been multiple proposals to change the way human
subjects are offered protection in research studies
(10,11). Finally, the mere process of “obtaining IRB
approval” (standard language in most submitted
manuscripts) does not mean that a given research
project is free of less obvious ethical problems. Power
calculations in a submitted trial may have been way
off, meaning that the performed research project
fails to reject its hypothesis with the required level of
signiﬁcance, or data collection may have been per-
formed in such a way as to lead to unacceptably high
conﬁdence limits. Even worse, a research project
may be abandoned or ﬁnished but never written up,
so that patients (or animals) were exposed to risk
without beneﬁt to the scientiﬁc community: the
Declaration of Helsinki clearly states that in-
vestigators have a duty to publish their results.
However, journals not infrequently receive manu-
scripts that may contain relevant results but are
written so poorly that the true value of the content is
impossible to assess. Some of the reports published
in iJACC have been substantially edited by the edi-
tors to make them comprehensible, but how much
effort must a journal’s reviewers and editors put
into issues of language to make a manuscript “pub-
lishable” so that the results become widely available?
Finally, ethical requirements will not be abso-
lutely equal in all cultures, countries, and in-
stitutions (12). The Declaration of Helsinki is the
unifying standard, stating, “Physicians should
consider the ethical, legal and regulatory norms
and standards for research involving human sub-
jects in their own countries as well as applicable
international norms and standards. No national or
international ethical, legal or regulatory require-
ment should reduce or eliminate any of the pro-
tections for research subjects set forth in this
Declaration.”
However, interpretation of the Declaration of
Helsinki may vary, and a very obvious example in
imaging is the exposure to contrast agents and,
especially, radiation, which requires speciﬁc appro-
val from government authorities in some countries,
while it is considered less problematic in others (13).
Does a journal based, for example, in the United
States (such as iJACC) have the right to question
IRB approval mandates from other countries with
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1353different operating rules? When does this cross over
into cultural snobbery and paternalistic attitudes? In
the end, do the rules of the country where research
was performed or the rules of the country where the
results are to be published have superior reign?
Although the Declaration of Helsinki provides
excellent guidance regarding the ethics of performing
and publishing medical research, there is clear po-
tential for conﬂict and uncertainties. The editors ofiJACC are committed to the highest standards in
research ethics, but we also understand that there are
shades of gray in this area. We look forward to
hearing your thoughts.
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